Sales of Merck’s new drug, Winrevair, more than doubled sequentially in the third quarter. The news could bolster downtrodden Merck stock.

The post Will Merck’s Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses? appeared first on Investor’s Business Daily.